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Abstract
Background: Pharmacological high-throughput screening (HTS) represents a powerful strategy
for drug discovery in genetic diseases, particularly when the full spectrum of pathological
dysfunctions remains unclear, such as in Friedreich ataxia (FRDA). FRDA, the most common
recessive ataxia, results from a generalized deficiency of mitochondrial and cytosolic iron-sulfur
cluster (ISC) proteins activity, due to a partial loss of frataxin function, a mitochondrial protein
proposed to function as an iron-chaperone for ISC biosynthesis. In the absence of measurable
catalytic function for frataxin, a cell-based assay is required for HTS assay.
Methods: Using a targeted ribozyme strategy in murine fibroblasts, we have developed a cellular
model with strongly reduced levels of frataxin. We have used this model to screen the Prestwick
Chemical Library, a collection of one thousand off-patent drugs, for potential molecules for FRDA.
Results: The frataxin deficient cell lines exhibit a proliferation defect, associated with an ISC
enzyme deficit. Using the growth defect as end-point criteria, we screened the Prestwick Chemical
Library. However no molecule presented a significant and reproducible effect on the proliferation
rate of frataxin deficient cells. Moreover over numerous passages, the antisense ribozyme
fibroblast cell lines revealed an increase in frataxin residual level associated with the normalization
of ISC enzyme activities. However, the ribozyme cell lines and FRDA patient cells presented an
increase in Mthfd2 transcript, a mitochondrial enzyme that was previously shown to be upregulated
at very early stages of the pathogenesis in the cardiac mouse model.
Conclusion: Although no active hit has been identified, the present study demonstrates the
feasibility of using a cell-based approach to HTS for FRDA. Furthermore, it highlights the difficulty
in the development of a stable frataxin-deficient cell model, an essential condition for productive
HTS in the future.
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In the past 20 years, many genes involved in different rare
genetic disorders have been identified. However, many
causative genes encode proteins of unknown or partially
known function, and with no predictable catalytic sites
enabling in vitro drug-target modeling. This makes drug
design and identification a difficult task for these orphan
diseases. However, new strategies based on automated
techniques for high-throughput screening (HTS) have
been developed, enabling cell-based assays to identify
drug-candidates.
Friedreich's ataxia (FRDA), the most common autosomal
recessive ataxia associating spinocerebellar ataxia and car-
diomyopathy [1,2], is most often due to a (GAA)n repeat
expansion within the first intron of the gene encoding the
mitochondrial protein frataxin [3,4]. This frequent muta-
tion leads to a severely reduced level of frataxin as a con-
sequence of transcriptional silencing either through
heterochromatin formation or through the formation of a
triplex helix [5-7]. Although much progress has been
made in understanding the physiopathology of FRDA, the
exact role of the frataxin protein is still unclear. Early stud-
ies showed iron deposits in cardiac tissue of FRDA
patients [8] and in the yeast strain deleted for frataxin
(ΔYFH1) thereby linking impaired iron homeostasis to
the disease [9]. This led to the hypothesis that elevated
levels of mitochondrial iron, as a consequence of frataxin
deficiency, could generate cell-damaging superoxide and
hydroxyl radicals through Fenton reaction. In support of
this, several studies have suggested an increased levels of
oxidative stress in patients [10-13], as well as an increased
sensitivity to oxidative stress in FRDA patients cells or
ΔYFH1-yeast model [14-18]. However, more recent stud-
ies have found no evidence of increased oxidative damage
in FRDA patients [19-21]. Moreover, experimental data
from the conditional FRDA mouse models demonstrated
that an increased superoxide production could not
explain by itself the FRDA pathology [22] and that the
mitochondrial iron accumulation is a late event in the dis-
ease [23]. In different mouse and cellular models, the pri-
mary biochemical event is the impaired function of iron-
sulfur cluster (ISC) proteins such as the aconitases and res-
piratory chain complexes I-III [23-26]. The role of frataxin
as a mitochondrial iron-chaperone for ISC biogenesis is
now widely accepted. In addition to severe alteration of
mitochondrial and extramitochondrial ISC proteins in
frataxin-deficient yeast, mice or human cells [23,27-30],
reconstitutional and in vivo studies demonstrate that the
yeast frataxin homolog Yfh1 is required, although not
essential, for ISC biosynthesis [27,29]. Furthermore,
frataxin has been demonstrated to interact with the ISC
biosynthesis scaffold complex IscU/Nfs1/ISD11 [31-35].
Several therapeutic strategies for FRDA have been devel-
oped based on the potential implication of these different
pathways in the pathogenesis. Some pharmacological
compounds such as antioxidants ([36] for review) or iron
chelators [37-39] have shown promise in improving some
of the symptoms of the disease. Recently, new therapeutic
strategies have been developed to address the frataxin
deficiency itself: pharmacological compounds increasing
frataxin protein levels (such as recombinant human eryth-
ropoietin) or reversing frataxin gene silencing (such as
histone deacetylase inhibitors) have been successfully
tested in clinical or preclinical trials [40,41]. However
there is currently no effective pharmacological treatment
available that would slow down the neurological progres-
sion of the disease in affected FRDA patients.
The development of a cellular model which reproduces
accurately the major aspects of the pathogenesis is the pre-
liminary condition before being able to make a pharma-
cological screen. To date, there is no appropriate
mammalian cell model for FRDA. Indeed, no easily avail-
able patient's tissue or cell lines spontaneously express the
generalized ISC enzyme deficiency, and exogenous stress
conditions have to be used in order to reveal a differential
phenotype with control fibroblasts [14,17,18,42]. Moreo-
ver, the reproducibility and relevance of the results
obtained with such systems has been contested [10]. More
recently, RNA interference strategies have been developed
to reproduce frataxin deficiency in mammalian cell lines
[16,25,43-47]. Both transient and stable frataxin silencing
to undetectable levels in HeLa cells lead to significant
reduction of cell growth and activities of ISC proteins
[45,47]. Although it seems evident that transient frataxin
silencing is not suitable for HTS experiments, it is unclear
whether the stable frataxin silencing clone in HeLa cells is
an appropriate model for HTS experiments as the clone is
reported to have roundish and grainy cells that easily
detached from the plate [47]. The RNAi models have been
studied to unravel consequences of frataxin deficiency,
but no HTS on a FRDA cell-model has yet been published.
In this study, we have developed and characterized a cel-
lular model with partial frataxin deficiency using targeted
ribozyme strategy. This model displayed a specific ISC
deficit, faithfully and spontaneously reproducing a key
feature of the human disease. The growth delay of the
frataxin-deficient clone was used as a quantifiable param-
eter to screen the Prestwick Chemical Library for potential
drug-candidates. However, the absence of confirmed
active hit and the instability of the cellular model illus-
trate the difficulty to identify drug-candidates in a small
compound library and in accurately replicating the FRDA
pathogenesis in a long-term controlled cellular model.
Methods
Ribozyme construction
The pZeoFxnR2, pZeoFxnR2m and pZeoFxnR5 vectors
were constructed using the pZeoU1EcoSpe vector [48,49].Page 2 of 10
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sense sequence, including the 24 highly conserved nucle-
otides of hammerhead ribozymes (underlined in the
sequences below) flanked by 24 and 15 nucleotides of
murine frataxin sequence in exon 2 for R2, and by 19 and
20 nucleotides of murine frataxin sequence in 3'-UTR at
the end of exon 5 for R5, were synthesized and annealed
at 42°C. The sequences of the oligonucleotides were as
follows: R2: 5'-AAT TCC TCA AAT GCA CCA CGC AGA
CTG ATG AGT CCG TGA GGA CGA AAC GCT CTG CTT
TTT GAT-3' and 5'-CTA GAT CAA AAA GCA GAG CGT
TTC GTC CTC ACG GAC TCA TCA GTC TGC GTG GTG
CAT TTG AGG-3' (sense and antisense, respectively); R5:
5'-AAT TAG GAG CAG GTA TGG GAA GGC AGA CTG
ATG AGT CCG TGA GGA CGA AAC ATT CAG CTA CAG
G-3' and 5'-CTA GCC TGT AGC TGA ATG TTT CGT CCT
CAC GGA CTC ATC AGT CTG CCT TCC CAT ACC TGC
TCC T-3' (sense and antisense, respectively). For the
mutated ribozyme R2m, the sequences of the oligonucle-
otides were as follows: R2m: 5'-AAT TCC TCA AAT GCA
AAA CGC AGA CTG ATG AGT CCG TGA GGA CGA AAC
GCT CTT ATT TTT GAT-3' and 5'-CTA GAT CAA AAA TAA
GAG CGT TTC GTC CTC ACG GAC TCA TCA GTC TGC
GTT TTG CAT TTG AGG-3' (sense and antisense, respec-
tively), which include four mismatches in the two frataxin
complementary sequences of exon 2 (bold in the primer
sequences). The resulting duplexes were ligated into the
EcoRI and SpeI sites of pZeoU1EcoSpe to create pZeoFxnR2
and pZeoFxnR2m. All ligation junctions were sequenced
to verify the identity and orientation of the insert.
Stable transfection of FrdaL2/L- cells
Murine fibroblast cell lines derived from mice carrying the
wild type (Frda+/+), conditional (Frda+/L3) or compound
heterozygous for the deleted and conditional (FrdaL3/L-)
frataxin alleles [23] were established using the primary-
explant technique [50], and then immortalized by trans-
fection with a Large Antigen T construct [51] using the
Fugene 6 Transfection Reagent kit (Roche, Indianapolis,
Indiana), according to the manufacturer's protocol. As the
mice also expressed an inducible recombinase (Cre-ERT)
[52], the deletion of the neomycin resistance cassette was
obtained by tamoxifen treatment. The resulting cell line
will be noted FrdaL2+/L- in the text.
FrdaL2+/L- immortalized cells were transfected with linear-
ized pZeoFxnR2 or pZeoFxnR2m. Stably transfected
fibroblasts were grown in DMEM media (Sigma, Saint
Louis, Missouri) with 10% fetal calf serum and 50 μg/ml
gentamycin, supplemented with 250 μg/ml Zeocin (Invi-
voGen, San Diego, California). Zeocin selection was
maintained one month. Monoclonal cell lines were
obtained by dilution cloning. Aliquots of the cell line
were frozen for cryopreservation in liquid nitrogen, and a
new aliquot was used for each screening experiment.
Genotyping and immunoblot analysis
Genotyping and DNA analysis were performed as previ-
ously described [23]. Immunoblot analysis using the anti-
frataxin antibody (R1250 purified sera, 1/1,000) were
performed as previously described [22,23]. Briefly, for
protein extract, fibroblast cell lines were lysed in a buffer
containing 50 mM Tris-HCl pH7.8, 10% (v/v) glycerol, 1
mM EDTA, 5 mM KCl with protease inhibitor (complete,
EDTA-free protease inhibitor cocktail (Roche, Basel, Swit-
zerland)). Cell lysates were sonicated and conserved at -
20°C.
Quantitative RT-PCR (Q-RT-PCR)
Expression levels of murine genes (Fxn, Mthfd2, Hprt)
were determined by Q-RT-PCR as previously described
[22,23]. The following primers were used for amplifica-
tion of human methylenetetrahydrofolate dehydrogenase
2 (MTHFD2) and 18S ribosome in the same conditions:
MTHFD2, forward 5'-TGA AGA GCG AGA AGT GCT GA-
3', reverse 5'-GAA TGC TCC CTG GTG AGG TA-3'. 18S,
forward, 5'-CGC CGC TAG AGG TGA AAT TC-3', reverse
5'-CTT TCG CTC TGG TCC GTC TT-3'.
Measurement of cell proliferation rates
Fibroblasts were plated in 6-well plates at day 1. After cell
detachment using trypsin, cell densities were determined
daily by visual counting with a hemocytometer. Four
counts were performed per well.
Biochemical analyses
Cells were harvested in PBS and dry pellet was immedi-
ately frozen in liquid nitrogen. The activities of the respi-
ratory chain enzyme complexes succinate cytochrome c
reductase (SCCR), cytochrome c oxydase (COX), the
mitochondrial and cytosolic aconitases (Aco) and the iso-
citrate deshydrogenase (IDH) as internal standard were
measured spectrophotometrically as previously described
[23,53].
Miniaturization and screening
The Prestwick Chemical Library (Illkirch, France) which
consists of 1120 drugs and bioactive natural compounds
approved by the Food and Drug Administration (FDA)
was screened on both R2C1 and R2m cell lines in 96-well
format. Chemical compounds (~5 mM) dissolved in
dimethyl sulfoxide (DMSO) were stored at -20°C into 96
well plates. Just before treatment, compounds were
diluted with cell culture medium (DMEM media with
10% fetal calf serum and 50 μg/ml gentamycin) into 96
well plates.
Fresh R2C1 and R2m cell aliquots were thawed for each
screening experiment. At the time of passage, R2C1 and
R2m cell suspensions were prepared in order to be seeded
into 96-well plates (Greiner Bio-one, France, ref 655090)Page 3 of 10
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tion (Beckman Coulter inc) (100 μl/well, 10,000 cells/
ml).
After sedimentation for 30 minutes, test compounds were
added to the wells (100 μl per well, one compound per
well) to result in a final concentration of 25 μM. Vehicle
control wells contained 0.5% DMSO alone (columns 1
and 12 of each plate). At this DMSO concentration we did
not detect any side effect on cells.
Cell proliferation was assessed 72 hours after cell treat-
ment using the commercial CellTiter-Glo Luminescent
Cell viability assay (Promega, Madison, WI) generating a
luminescent signal directly proportional to the amount of
ATP present in metabolically active cells. After incubation,
100 μl of medium was removed and replaced by 100 μl of
Promega CellTiter-Glo reagent to each well using the
Biomek 2000 workstation. Plates were shaken for 5 min
on a plate shaker before reading luminescence on a
Victor3 plate reader (PerkinElmer, Norwalk, CT). Lumi-
nescence in each treated well was compared to the mean
signal obtain in non-treated wells (columns 1 and 12).
Positive hits were designated for any compounds with
luminescent signal over three standard deviations when
compared to untreated control wells. Luminescent ratio
between the R2m and R2C1 cell lines was also calculated
to check the reproducibility of proliferation delay in the
frataxin deficient clone during the experiments (when cal-
culated for non treated cells) and to check the specificity
of drug action (when calculated for treated cells).
Results
Partial loss of frataxin leads to a proliferation defect in 
frataxin ribozyme cell lines
To generate viable FRDA cellular models with reduced
frataxin level, we used a ribozyme antisense strategy in
cells derived from mice carrying the conditional allele
[23]. Two ribozymes, one targeted against exon 2 of the
murine frataxin mRNA and one against the 3'-UTR (exon
5), were constructed in the U1snRNA based ribozyme vec-
tor pZeoSV [49]. Immortalized compound heterozygous
FrdaL2+/L- cells were transfected with either a frataxin-spe-
cific ribozyme (pZeoFxnR2 or pZeoFxnR5) or a control
construct bearing mutant frataxin sequences
(pZeoFxnR2m). The transfected cell lines were subse-
quently brought through the identical selection process to
generate polyclonal and monoclonal colonies of stable
transfectants. Two clones were obtained with pZeoFxnR2
(R2C1 and R2C2) and four with pZeoFxnR5 (R5C1 to
R5C4). The amount of frataxin was assayed by Q-RT-PCR
and western blot. A better frataxin knockdown was
obtained with the pZeoFxnR2 clones compared to the R5
clones (Fig. 1). Clones transfected with mutant-
pZeoFxnR2m showed no significant difference compared
to non-transfected FrdaL2+/L- cells (data not shown). For
subsequent experiments, we selected the two R2 clones
(R2C1 and R2C2) which presented significant decrease in
frataxin mRNA and protein expression levels (frataxin
residual protein level: 9.4% ± 6.1 (p < 0.001) and 18.0%
± 8.4 (p < 0.001), respectively; frataxin mRNA level:
16.5% ± 4.7 (p < 0.001) and 24.9% ± 4.0 (p < 0.001),
respectively) (Fig. 1B).
The frataxin deficient clones R2C1 and R2C2 consisted of
a homogeneous cell population with no gross morpho-
logical phenotype or cell death. Electron microscopy anal-
yses confirmed the absence of morphological phenotype,
with normal mitochondria having clear thin cristae and
no iron deposits (data not shown). However, growth
analysis uncovered a clear proliferation defect in both
frataxin deficient clones (Fig. 2). Indeed, the two clones
(R2C1 and R2C2) grew slower than FrdaL2+/L- non-trans-
fected cells, leading to 90% and 77% reduction of cell
number, respectively, after 4 days in culture. In addition,
both R2C1 and R2C2 grew slower than R2m clones (see
below).
Depletion of frataxin in ribozyme clonesFigure 1
Depletion of frataxin in ribozyme clones. (A) Repre-
sentative western blot analyses of protein extracts from dif-
ferent ribozymes clones revealed with polyclonal frataxin 
antibody is shown (five independent experiments were per-
formed for quantitative analysis in B). Normalization was 
done using β-tubulin as a loading control. (B) Frataxin mRNA 
(white) and protein (grey) levels in antisense ribozyme 
fibroblast clones R2C1, R2C2, R5C1 and R5C2, compared to 
the FrdaL2+/L- non-transfected cell line. Three quantitative-
RT-PCR analyses were performed on whole cellular RNA 
extracts, comparing frataxin expression to the reference 
Hprt gene. *p ≤ 0.05; ***p ≤ 0.005.Page 4 of 10
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protein activities
Frataxin deficiency in FRDA patients and in model organ-
isms (mice, drosophila, and yeast) leads to a specific def-
icit in the ISC protein activities [23,30,54]. The enzymatic
activities of mitochondrial respiratory chain succinate
cytochrome c reductase (SCCR) and cytochrome c oxy-
dase (COX), the tricarboxylic acid cycle enzymes aconi-
tases (Aco), and isocitrate dehydrogenase (IDH) were
measured spectrophotometrically in the frataxin-deficient
clones compared to FrdaL2+/L- non-transfected cells. Inter-
estingly, the two ISC enzymes (SCCR and Aco) showed a
decreased activity in frataxin deficient clones (Fig. 3) with
a SCCR/COX ratio of 1.56 ± 0.23 and an Aco/IDH ratio of
1.94 ± 0.16 in the frataxin deficient clones while the
SCCR/COX and the Aco/IDH ratios were 1.97 ± 0.09 and
3.66 ± 0.34 in the control cells, respectively (Fig. 3). More-
over the data parallel previous results from both FRDA
patients and mouse models suggesting that the aconitases
are more sensitive to frataxin deficiency than SSCR.
Indeed, we found a 45% decrease in activity of aconitases
with only a 19% decrease in SSCR activity in the ribozyme
clones.
Medium-scale pharmacological screen of the ribozyme cell 
model
The proliferation delay of frataxin-deficient clones is an
assay readout that is amenable to downscaling to 96-well
plate format for easy automation. Set-up experiments
were performed in order to select the best mutant cell line
(R2C1 or R2C2), the seeding concentration (100 to 1,000
cells per well) and the time of culture before reading (3 or
4 days). Four different methods were tested to measure
cell proliferation, based on nucleic acid detection
(CyQUANT cell proliferation assay, Molecular Probe),
ATP production (CellTiter-Glo Luminescent Cell Viability
Assay, Promega) or reduction of tetrazolium salt (MTT test
and CellTiter 96 AQueous Cell Proliferation Assay,
Promega). The CellTiter-Glo assay showed the best results
with a growth ratio (R2m control cells/R2C1 frataxin defi-
cient cells) of 1.87 (corresponding to a 47% decrease
growth rate for the frataxin-deficient clone) and the small-
est standard deviation after 3 days. No major decantation
effect or edge effect was detected. Due to contact inhibi-
tion of the cells occurring when confluence is reached into
96-well plates, the optimal time for output readings was
72 hrs after seeding.
Using the established screening conditions, the Prestwick
Chemical Library, a collection of off-patent drugs and
alkaloids, was screened to find candidate pharmacologi-
cal compounds that could rescue the proliferation defect
of the frataxin deficient cell line. The 1,120 molecules of
the library were tested at a single concentration of 25 μM
in 96-well format (Fig. 4A) using the CellTiter-Glo lumi-
nescent cell viability assay. We performed the screen on
both frataxin deficient (R2C1) and control (R2m) cell
lines. The Z'-factor classically used in evaluation and vali-
dation of HTS assays [55] cannot be evaluated in this
screen as positive controls on cell growth were not availa-
ble. The statistical analysis of luminescence intensity for
frataxin-deficient (R2C1) and control (R2m) untreated cell
lines during the primary screening showed a good growth
ratio with small standard deviation (Fig. 4B). The coeffi-
cients of variation (CV) are within the acceptable range for
a cell-based assay; i.e. below 10%. The control cell line
proliferation rate was 2.10 ± 0.14 times higher when com-
pared to the frataxin-deficient clone. Positive hits were
designated for any compound with cellular growth incre-
ment over three standard deviations (increase in lumines-
cence intensity as compared to untreated control wells of
Frataxin depletion impaired cell growthigure 2
Frataxin depletion impaired cell growth. Growth 
curves on the frataxin-deficient clones R2C1 and R2C2 com-
pared to the FrdaL2+/L- non-transfected cell line.
Frataxin depletion impaired ISC-enzymes activitiesigure 3
Frataxin depletion impaired ISC-enzymes activities. 
ISC-proteins activities in frataxin-deficient R2 clones (R2C1 
and R2C2) and non-transfected control cell line. As the data 
was equivalent, data of both frataxin deficient clones were 
pooled for representation. SCCR (succinate cytochrome c 
reductase, respiratory chain complex II) and aconitases (Aco) 
are ISC proteins while COX (cytochrome c oxidase, respira-
tory chain complex IV) and IDH (isocitrate dehydrogenase) 
do not contain an ISC.Page 5 of 10
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Screening of the Prestwick Chemical LibraryFigure 4
Screening of the Prestwick Chemical Library. (A) Schematic representation of the three-step screening with hits yields. 
(B) Luminescence intensity of frataxin-deficient (R2C1) and control (R2m) untreated cell lines during the primary screening (14 
plates for each cell line). Mean (M), standard deviation (SD), coefficient of variation (CV). (C) Effect of the 1,120 compounds of 
the library on the luminescence intensity in the control cell line R2m (upper panel) and in the frataxin-deficient clone R2C1 
(lower panel) during the primary screening. Results are expressed as percentage of luminescence intensity compared to the 
same non treated cell line.
BMC Neurology 2009, 9:46 http://www.biomedcentral.com/1471-2377/9/46the same cell line). Eighty-seven primary hits were identi-
fied in the primary screening: fifty molecules increased
proliferation rate in frataxin deficient cell line only, forty-
six in the control cell line only and nine molecules had
proliferative effect on both cell lines (Fig. 4C). All eighty-
seven primary hits were tested for confirmation at two
concentrations (2.5 and 25 μM) in duplicate, using the
same hit selection criteria. Eighteen hits were retained
with proliferative though minor effect, and were fol-
lowed-up in a dose-response analysis. Each compound
was tested at five concentrations (1, 3, 10, 30 and 100 μM)
with four wells per concentration. However at this stage,
no molecule presented a significant and reproducible
strong effect on the proliferation rate of the frataxin defi-
cient cell line (Fig. 4A).
Instability of the frataxin deficiency in the ribozyme cell 
lines
It is important to note that the R2C1 ribozyme cell line
underwent numerous passages over a period of two years
during the entire model set up and screening develop-
ment. We therefore were interested in testing the stability
of frataxin deficiency on different aliquots throughout the
screening period. Despite the presence of the ribozyme
(both at the genomic and RNA level, data not shown), Q-
RT-PCR demonstrated that the frataxin mRNA level had
increased by 1.8 fold (with a basal frataxin expression
from 16 ± 5% to 29 ± 7% of wild type level). This
"adjusted level" of frataxin deficiency was still associated
with a deficit in the proliferation rate (by manual count-
ing: 1,97 ratio at day 3 and 65% reduction of cell number
at day 4), but the ISC protein activities (SCCR and aconi-
tases) deficit was no longer present. The R2C1 cell line
therefore became similar to FRDA patient's fibroblasts
where no ISC enzyme deficiency can be found. However,
Q-RT-PCR demonstrated that the "adjusted level" R2C1
cell line, in addition to the proliferation deficit, presented
an increase of the Mthfd2 transcript (Fig. 5A), a transcrip-
tional change associated with frataxin deficiency in mouse
models [22] and FRDA fibroblasts (Fig. 5B).
Discussion
Cellular models are of great value for drug screening strat-
egies and often represent an essential tool for both inves-
tigating molecular mechanisms of genetic diseases and
identifying pharmacologically active compounds. We
have used an antisense ribozyme strategy to establish a
cell line with reduced frataxin level. Two clones presented
a significant decrease in frataxin with a clear decrease in
cell proliferation. Moreover, these frataxin deficient cells
initially showed a deficit in the activity of two ISC
enzymes (45% decrease in aconitase activity and 19%
decrease in SCCR activity), a specific and characteristic
feature of the human disease.
Our results on the ribozyme cell lines are in agreement
with data observed in both transient and stable frataxin
silencing models in HeLa cells obtained by RNAi strate-
gies [45,47]. Upon frataxin depletion below ~20%, the
three models display reduction of growth and decreased
activity of the ISC proteins, specifically aconitases and suc-
cinate dehydrogenase. However, one notable difference is
the altered morphology observed in the stable RNAi HeLa
cell line, with roundish and grainy cells that easily
detached from the plate [47]. This abnormal morphology
is most likely due to the strongly reduced level of frataxin
(almost undetectable) in the stable RNAi HeLa model
compared to the normal phenotype of cells presenting
approximately 10 to 20% of residual frataxin ([45] and
this manuscript). Indeed, no clone with a frataxin level
below 9% was found in the present study. In agreement
with these results, we have recently shown that complete
absence of frataxin in murine fibroblasts inhibits cell divi-
Mthfd2 expression level in ribozyme clones and in FRDA patient's fib oblastsFigure 5
Mthfd2 expression level in ribozyme clones and in 
FRDA patient's fibroblasts. (A) Quantitative-RT-PCR 
analyses were performed on three different cellular RNA 
extracts of R2m and R2C1 clones, comparing the expression 
of murine Mthfd2 transcript to the reference Hprt transcript. 
The R2C1 cells used for these experiments present the 
"adjusted" frataxin residual level of 29 ± 7%. (B). Quantita-
tive-RT-PCR analyses were performed on two different cel-
lular RNA extracts of FRDA (n = 3) and control (n = 5) 
fibroblasts, comparing expression of the human MTHFD2 
transcript to 18S ribosome transcript. ***p ≤ 0.005.Page 7 of 10
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observations suggest that a threshold level of frataxin is
necessary for cell proliferation and survival, consistent
with the early embryonic lethality of the classical knock-
out mouse model [56].
While some candidate-based pharmacological com-
pounds such as antioxidants ([36] for review) or iron che-
lators [37] have shown some promising results in clinical
trial in providing protection on certain aspects of the dis-
ease, there is still no effective therapy for FRDA. Moreover
clinical drug trials are difficult to organize for a disease
like FRDA, due to the slowly progressive and chronic
nature of the disease, the very large individual variations
(due in part to the unstable expansion mutation), the low
frequency of the disease, and the ethical issues raised by
double-blind testing. Cellular models of the human dis-
ease short-cut all these problems, and should allow to
obtain faster and more reliable results on efficacy of new
compounds in pre-clinical trials. We have therefore used
our frataxin-deficient cell line to perform a pharmacolog-
ical robotized screening. Indeed, HTS has revealed to be a
successful strategy for drug discovery, especially when
rational design based on the knowledge of the molecular
cause of the pathological dysfunction is unclear. To cir-
cumvent the limitations of screening large libraries, we
have chosen to study a limited number of already availa-
ble drug molecules, in accordance to the "selective optimi-
zation of side activities" (SOSA) approach [57]. Indeed,
the Prestwick Chemical Library consists in 1,120 com-
pounds that are structurally and therapeutically very
diverse with known safety and bioavailability in humans.
Despite the identification of 87 primary hits, 18 of which
were confirmed at the secondary step, no molecule of the
library has revealed a significant and reproducible positive
effect on cell growth of the frataxin-deficient clone on a
dose-response curve. This failure may be due to the rather
aspecific assay readout chosen to follow the efficiency of
the molecules. Indeed, cell proliferation is under the con-
trol of multiple regulatory pathways and could lead to
high rate of false positive and negative results. The activi-
ties of ISC proteins would probably be a more suitable
end-point for FRDA screening but these enzymatic meas-
urements are not available for automated quantification.
A second explanation to this unproductive screen could
be the rather low number of tested molecules. Knowing
that such screening strategies retrieves between 0.1 and
1% of hits, it is statistically not surprising not to find a hit
in a 1,120 compounds library. The screen of a larger com-
pound library could allow to find active compounds. In
spite of the absence of positive hit, this first cell-based
automated screen on a FRDA cell model demonstrates the
feasibility of the strategy.
The primary screen also identified one hundred and fifty
one molecules decreasing ATP production in frataxin defi-
cient and/or control cell lines. Two molecules specifically
reduced the proliferation rate of the frataxin deficient
clone. Although at first sight, the mecanism of action of
both molecules (one expectorant and one vasodilatator)
is hard to link to the current knowledge on frataxin, fur-
ther investigation may uncover new pathways linked to
frataxin.
Long term maintenance of the R2C1 frataxin-deficient
clone has revealed a cellular adaptation to frataxin defi-
ciency. Despite the persistence of the ribozyme construc-
tion, frataxin mRNA level has increased from 16 to 29%
by an unknown compensatory mechanism, either by an
increase in transcription or stability of the endogenous
Fxn transcript, or by a reduction of the ribozyme effi-
ciency. This slight increase in frataxin level was sufficient
to restore normal ISC enzyme activities whereas prolifera-
tive deficit of the frataxin-deficient clone was still present.
Furthermore, the Mthfd2 transcript, a mitochondrial
enzyme involved in reduction of folate cofactors, was
increased in the R2C1 clone, as previously observed at
very early stages of pathogenesis in the cardiac mouse
models [22] and also in FRDA fibroblasts (this manu-
script). These data demonstrate the difficulty in obtaining
stable cell line deficient in frataxin and could explain the
paucity of long term stable models, necessary for pharma-
cological screening. As the long term persistence of
frataxin deficiency was not tested in the stable RNAi
model [47], we do not know if this adaptative mechanism
is specific to our antisense strategy or is a more general fea-
ture characteristic of frataxin deficient cell lines.
Conclusion
The present work demonstrates the feasibility of a cell-
based high-throughput screening assay in Friedreich
ataxia but highlights the necessity of developing long-
term robust cellular model that reproduce the physiopa-
thology of the disease. Furthermore, the readout for the
screen should be as specific as possible, in accordance to
technical limitations.
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